Geneos Wealth Management’s MiMedx Group MDXG Stock Holding History

Geneos Wealth Management’s Portfolio MDXG Stock Details MDXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.29K	Hold	2,100	–	–	﹤0.01%	2036
2025 Q4	$14.2K	Hold	2,100	–	–	﹤0.01%	1856
2025 Q3	$14.7K	Hold	2,100	–	–	﹤0.01%	1835
2025 Q2	$12.8K	Sell	2,100 -700	-25%	-$4.66K	﹤0.01%	2220
2025 Q1	$21.3K	Buy	2,800 +2,100	+300%	+$17.5K	﹤0.01%	2294
2024 Q4	$6.73K	Hold	700	–	–	﹤0.01%	2211
2024 Q3	$4.14K	Hold	700	–	–	﹤0.01%	2124
2024 Q2	$4.85K	Hold	700	–	–	﹤0.01%	1728
2024 Q1	$5.39K	Hold	700	–	–	﹤0.01%	1695
2023 Q4	$6.14K	Hold	700	–	–	﹤0.01%	1680
2023 Q3	$5.1K	Sell	700 -2,000	-74%	-$14.9K	﹤0.01%	1741
2023 Q2	$17.8K	Hold	2,700	–	–	﹤0.01%	1419
2023 Q1	$9.21K	Hold	2,700	–	–	﹤0.01%	1575
2022 Q4	$7.51K	Hold	2,700	–	–	﹤0.01%	1610
2022 Q3	$7K	Sell	2,700 -13,600	-83%	-$48.3K	﹤0.01%	1613
2022 Q2	$58K	Sell	16,300 -215	-1%	-$842	﹤0.01%	1222
2022 Q1	$77K	Buy	16,515 +500	+3%	+$2.44K	﹤0.01%	1191
2021 Q4	$96K	Buy	16,015 +2,100	+15%	+$14.6K	﹤0.01%	1187
2021 Q3	$82K	Buy	13,915 +4,000	+40%	+$45.1K	﹤0.01%	1251
2021 Q2	$122K	Hold	9,915	–	–	﹤0.01%	1083
2021 Q1	$96K	Sell	9,915 -2,000	-17%	-$19.3K	﹤0.01%	1329
2020 Q4	$120K	Sell	11,915 -750	-6%	-$5.4K	﹤0.01%	1057
2020 Q3	$81K	Hold	12,665	–	–	﹤0.01%	1038
2020 Q2	$68K	Sell	12,665 -500	-4%	-$2.69K	﹤0.01%	1085
2020 Q1	$48K	Buy	13,165 +900	+7%	+$3.28K	﹤0.01%	1127
2019 Q4	$88K	Sell	12,265 -150	-1%	-$1.08K	﹤0.01%	993
2019 Q3	$61K	Hold	12,415	–	–	﹤0.01%	1087
2019 Q2	$50K	Hold	12,415	–	–	﹤0.01%	1183
2019 Q1	$43K	Hold	12,415	–	–	﹤0.01%	1219
2018 Q4	$18K	Sell	12,415 -23	-0.2%	-$128	﹤0.01%	1547
2018 Q3	$76K	Sell	12,438 -52	-0.4%	-$235	0.01%	985
2018 Q2	$79K	Buy	12,490 +215	+2%	+$1.53K	0.01%	863
2018 Q1	$85K	Buy	12,275 +5,152	+72%	+$60K	0.01%	814
2017 Q4	$89K	Buy	7,123 +500	+8%	+$6.1K	0.01%	786
2017 Q3	$78K	Buy	6,623 +334	+5%	+$4.95K	0.01%	782
2017 Q2	$94K	Sell	6,289 -1,222	-16%	-$16.3K	0.01%	701
2017 Q1	$71K	Buy	7,511 +400	+6%	+$3.38K	0.01%	767
2016 Q4	$63K	Hold	7,111	–	–	0.01%	751
2016 Q3	$61K	Sell	7,111 -1,535	-18%	-$12.2K	0.01%	746
2016 Q2	$71K	Sell	8,646 -2,270	-21%	-$17.7K	0.01%	687
2016 Q1	$98K	Buy	+10,916	New	+$90.7K	0.02%	589

Other funds holding MDXG

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $418M AUM 3.34% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Geneos Wealth Management's MDXG Position: Q1 2026 in Review

Geneos Wealth Management held its MiMedx Group (MDXG) position steady in Q1 2026 at 2,100 shares worth $8.29K. The position accounts for ﹤0.01% of the portfolio, ranked #2036.

Geneos Wealth Management first reported a position in MDXG in Q1 2016 and has held it in 41 quarters since. The position peaked at $122K in Q2 2021. 237 funds tracked by Wall St. Rank hold MDXG as of Q1 2026.

Geneos Wealth Management held 2,100 shares of MiMedx Group worth $8.29K as of Q1 2026.
Geneos Wealth Management left its MiMedx Group share count unchanged in Q1 2026.
MiMedx Group made up ﹤0.01% of Geneos Wealth Management's portfolio in Q1 2026, its #2036 holding.
Geneos Wealth Management first reported a position in MiMedx Group in Q1 2016 and has held it in 41 quarters since.
Geneos Wealth Management's MiMedx Group position peaked at $122K in Q2 2021.
237 funds tracked by Wall St. Rank held MiMedx Group as of Q1 2026.

Based on Geneos Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.